CTOs on the Move

Arena Pharmaceuticals

www.arenapharm.com

 
We are a biopharmaceutical company focused on developing novel, small molecule drugs with optimized receptor pharmacology designed to deliver broad clinical utility across multiple therapeutic areas. Our proprietary pipeline includes potentially first- or best-in-class programs for which we own global commercial rights. Arena is headquartered in San Diego, CA, with operations in Boston, MA, and Zug, Switzerland.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
John Lamoureux
Director, Global IT Infrastructure and Security Profile

Similar Companies

Oncology Therapeutics Network

Oncology Therapeutics Network is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sound Pharmaceuticals

Sound Pharmaceuticals is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ocularis Pharma

Ocularis Pharma, Inc. is a Riverside, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Verséa Health

Verséa Health is a diversified global healthcare company engaged in scientific discovery, development and commercialization of innovative products and services intended to diagnose, manage, and treat debilitating diseases.

Pharvaris

Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.